MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Phase 1
Completed
Conditions
Obesity
Interventions
First Posted Date
2024-03-04
Last Posted Date
2025-05-11
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
34
Registration Number
NCT06289504
Locations
🇨🇦

Altasciences Company Inc., Mount-Royal, Quebec, Canada

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2024-02-26
Last Posted Date
2024-12-05
Lead Sponsor
Bayer
Target Recruit Count
320
Registration Number
NCT06278051
Locations
🇯🇵

Many facilities, Multiple Locations, Japan

🇯🇵

Bayer, Osaka, Japan

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

First Posted Date
2024-01-22
Last Posted Date
2025-03-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
16
Registration Number
NCT06215430
Locations
🇺🇸

Covance Clinical Research Unit, Dallas, Texas, United States

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE

Phase 4
Recruiting
Conditions
Antiphospholipid Syndrome
Ischemic Stroke
Transient Ischemic Attack
Cerebrovascular Disease
Cardiovascular Diseases
Major Bleed
Interventions
Drug: Antiplatelet Drug
First Posted Date
2023-08-16
Last Posted Date
2024-10-16
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
200
Registration Number
NCT05995600
Locations
🇰🇷

Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of

🇰🇷

Busan Paik Hospital, Busan, Korea, Republic of

🇰🇷

Yeungnam University Medical Center, Daegu, Korea, Republic of

and more 29 locations

"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.

Not yet recruiting
Conditions
Patients With Atrial Fibrillation Receiving Oral Anticoagulants
First Posted Date
2023-08-03
Last Posted Date
2023-08-03
Lead Sponsor
Sohag University
Target Recruit Count
100
Registration Number
NCT05975320

Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial

Phase 4
Recruiting
Conditions
Left Ventricular Thrombus
Interventions
First Posted Date
2023-08-02
Last Posted Date
2023-08-02
Lead Sponsor
Peshawar Institute of Cardiology
Target Recruit Count
141
Registration Number
NCT05973188
Locations
🇵🇰

Peshawar Institute of Cardiology, Peshawar, KPK, Pakistan

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Early Phase 1
Completed
Conditions
Atopic Dermatitis
Interventions
Dietary Supplement: Caffeine
Dietary Supplement: Vitamin K
First Posted Date
2023-06-06
Last Posted Date
2025-01-20
Lead Sponsor
Amgen
Target Recruit Count
21
Registration Number
NCT05891119
Locations
🇺🇸

Direct Helpers Research Center (DHRC), Hialeah, Florida, United States

🇺🇸

Velocity Clinical Research -Spartanburg, Spartanburg, South Carolina, United States

🇺🇸

DermDox Dermatology Centers, PC - Sugarloaf, Nashville, Tennessee, United States

and more 4 locations

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Completed
Conditions
Atrial Fibrillation
Interventions
First Posted Date
2023-05-01
Last Posted Date
2024-05-17
Lead Sponsor
Pfizer
Target Recruit Count
3691397
Registration Number
NCT05838664
Locations
🇫🇷

Pfizer Investigational Site, Paris, France

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Phase 1
Completed
Conditions
Overweight Subjects
Obese Subjects
Interventions
First Posted Date
2023-04-18
Last Posted Date
2023-11-14
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
48
Registration Number
NCT05815680
Locations
🇨🇳

Aerospace Center Hospital, Beijing, Beijing, China

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2023-04-03
Last Posted Date
2024-11-22
Lead Sponsor
Pfizer
Target Recruit Count
13945
Registration Number
NCT05795062
Locations
🇺🇸

Pfizer, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath